Anne Wojcicki regains control of 23andMe, the company she co-founded and led as CEO, through her nonprofit TTAM with a $305 million bid at a bankruptcy auction.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

A bankruptcy court this week approved the $305 million sale of genetics testing firm 23andMe to a nonprofit organization led ...

In a surprise twist, 23andMe founder and former CEO Anne Wojcicki is set to regain control of the DNA company's assets, according to a press release from 23andMe. In May, a company called ...

That means Wojcicki’s nonprofit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe’s ...

Anne Wojcicki, the co-founder and former CEO of 23andMe, is poised to regain control of the DNA-testing company after a nonprofit she controls topped a prior bid. 23andMe said Friday that a ...

Former 23andMe CEO Anne Wojcicki now runs TTAM Research Institute, which outbid Regeneron in an auction for the bankrupt company’s assets.

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe's co-founder ...